ISCO welcomes abstracts from all areas of treatment, nursing, basic sciences and translational research in SOLID TUMORS.
After passing of abstract submission deadline for oral presentations, we just accept abstracts for poster presentation.
Iranian Clinical Oncology congress is designed to improve cancer care in Iran, so it has CME credits for all specialties who involved in cancer care.
9:00 – 9:30: Immuno-oncology a new way in treatment of cancer
9:30 – 10: New approval immunotherapy in treatment of cancer (breast, lung, skin, head&neck, GI, GU and GYN cancers)
10 – 10:30: Panel: Cancer and health economy issue?
8:30 – 8:50: Treatment choices in RCC: considering prognostic scoring, efficacy & safety & sequencing
8:50 – 9:10: Neoadjuvant Vs adjuvant therapy in muscle invasive bladder cancer
9:10 – 9:30: Treatment of Metastatic Castration-Sensitive/-Naïve Prostate Cancer
9:30 – 10:30: Panel Treatment of oligo-metastatic PCaRead More
10:50 – 11:10: Brachytherapy in gynecology cancer
11:10 – 11:30: Debate; Neoadjuvant chemotherapy versus primary radiochemotherapy in FIGO IB2 cervical cancer
11:30 – 11:50: Intraperitoneal, hyperthermic intraperitoneal and HIPEC chemotherapy
11:50 – 12:10: Strategies for patients with ovarian cancer who have received multiple prior therapies
12:10 – 13:20: Panel: Management of locally advance ovarian cancerRead More
8:30 – 8:50: Metastasectomy for whom and when?
8:50 – 9:10: Non surgical Ablation therapy in metastatic patients
9:10 – 9:30: SBRT for metastases
9:30 -9:50: Primary tumor treatment instead of unresectable metastatic disease for which tumor?
9:50 – 10:30: Panel; case discussion (Patients with Unresectable Metastatic CancerRead More
10:50 – 11:10: Gastric cancer (Patient with Gastric Cancer with + Peritoneal Cytology on Preop Laparoscopy—Palliate or Operate?
11:10 – 11:30: Pancreatic cancer ; Adjuvant or neoadjuvant chemoradiation in resectable pancreatic cancer
11:30 – 11:50: Rectal cancer; watch and wait policy in clinical complete response after neoadjuvant chemoradiation; the gains and pitfalls
11:50 – 12:10: Metastatic colorectal cancer Debate; Standard Chemotherapy or Targeted Approaches?
12:10 – 13:20: Panel; What is the best curative treatment strategy for a patient with synchronous rectal cancer and liver limited metastases?Read More